Listar por tema "drug approval"

Ordenar por:Orden:Resultados:

  • Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management 
    Carrá, A.; Macías Islas, M.A.; Tarulla, A.; Bichuetti, D.B.; Finkelsztejn, A.; Dadalti Fragoso, Y.; Árcega-Revilla, R.; Cárcamo Rodríguez, C.; Durán, J.C.; García Bonitto, J.; León, Rosalba; Oehninger Gatti, C.; Orozco, G.; Vizcarra-Escobar, Darwin (Taylor and Francis, 2015)
    Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and ...
  • Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents 
    Finkelsztejn, A.; Gabbai, A.A.; Fragoso, Y.D.; Carrá, A.; Macías-Islas, M.A.; Arcega-Revilla, R.; García-Bonitto, J.; Oehninger-Gatti, C.L.; Orozco-Escobar, G.; Tarulla, A.; Vergara, F.; Vizcarra-Escobar, Darwin (SP Academia Brasileira de Neurologia, 2012)
    Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and NorthAmerican algorithms for the treatment of multiple sclerosis do not foresee our regional ...
  • Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America 
    Steinberg, Judith; Fragoso, Yara D.; Duran Quiroz, Juan Carlos; Garcia, Juan Raul; Guerra, Caroline; Rodriguez, Virginia; Carcamo Rodriguez, Claudia; Ciampi, Ethel; Correa-Diaz, Edgar; Macias, Miguel; Novarro, Nelson; Vizcarra-Escobar, Darwin; Oehninger Gatti, Carlos; Orozco, Geraldine; Carra, Adriana (Springer, 2019)
    The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient ...

Buscar en el Repositorio

Listar

Panel de Control